ECSP088816A - Anticuerpos contra el receptor del factor de crecimiento i similar a la insulina y usos de los mismos - Google Patents
Anticuerpos contra el receptor del factor de crecimiento i similar a la insulina y usos de los mismosInfo
- Publication number
- ECSP088816A ECSP088816A EC2008008816A ECSP088816A ECSP088816A EC SP088816 A ECSP088816 A EC SP088816A EC 2008008816 A EC2008008816 A EC 2008008816A EC SP088816 A ECSP088816 A EC SP088816A EC SP088816 A ECSP088816 A EC SP088816A
- Authority
- EC
- Ecuador
- Prior art keywords
- insulin
- receiver
- similar
- same
- growth factor
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
- 102000004877 Insulin Human genes 0.000 title 1
- 108090001061 Insulin Proteins 0.000 title 1
- 239000003102 growth factor Substances 0.000 title 1
- 229940125396 insulin Drugs 0.000 title 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 abstract 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 abstract 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 abstract 1
- FDJKUWYYUZCUJX-AJKRCSPLSA-N N-glycoloyl-beta-neuraminic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-AJKRCSPLSA-N 0.000 abstract 1
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06007571 | 2006-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP088816A true ECSP088816A (es) | 2008-11-27 |
Family
ID=36940705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2008008816A ECSP088816A (es) | 2006-04-11 | 2008-10-09 | Anticuerpos contra el receptor del factor de crecimiento i similar a la insulina y usos de los mismos |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20080014203A1 (enExample) |
| EP (2) | EP2007810B1 (enExample) |
| JP (1) | JP4718634B2 (enExample) |
| KR (2) | KR101276513B1 (enExample) |
| CN (1) | CN101421305B (enExample) |
| AR (1) | AR060592A1 (enExample) |
| AU (1) | AU2007236199B2 (enExample) |
| BR (1) | BRPI0710185B8 (enExample) |
| CA (2) | CA2647181C (enExample) |
| CR (1) | CR10301A (enExample) |
| EC (1) | ECSP088816A (enExample) |
| ES (1) | ES2403075T3 (enExample) |
| IL (1) | IL194397A (enExample) |
| MX (1) | MX2008012950A (enExample) |
| NO (1) | NO20084082L (enExample) |
| NZ (1) | NZ571414A (enExample) |
| RU (1) | RU2541765C2 (enExample) |
| UA (1) | UA95284C2 (enExample) |
| WO (1) | WO2007115814A2 (enExample) |
| ZA (1) | ZA200808597B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7846724B2 (en) * | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| TW200833711A (en) * | 2006-12-22 | 2008-08-16 | Genentech Inc | Antibodies to insulin-like growth factor receptor |
| PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| CN101903401B (zh) | 2007-12-21 | 2013-06-05 | 罗切格利卡特公司 | 抗体的稳定性试验 |
| SI2376116T1 (sl) | 2008-12-12 | 2016-03-31 | Boehringer Ingelheim International Gmbh | Anti-IGF protitelesa |
| WO2010112194A1 (en) * | 2009-04-02 | 2010-10-07 | F. Hoffmann-La Roche Ag | Antigen-binding polypeptides and multispecific antibodies comprising them |
| US20100316639A1 (en) | 2009-06-16 | 2010-12-16 | Genentech, Inc. | Biomarkers for igf-1r inhibitor therapy |
| EP2456547B2 (en) | 2009-07-24 | 2024-03-06 | F. Hoffmann-La Roche AG | Stirrer system |
| WO2011044336A2 (en) | 2009-10-07 | 2011-04-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human domain antibodies against components of the human insulin-like growth factor (igf) system |
| BR122022001178B1 (pt) | 2009-10-26 | 2022-10-04 | F. Hoffmann-La Roche Ag | Método para a produção de uma imunoglobulina glicosilada e seu uso |
| US20110200595A1 (en) | 2010-02-18 | 2011-08-18 | Roche Glycart | TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR |
| WO2011135040A1 (en) | 2010-04-30 | 2011-11-03 | F. Hoffmann-La Roche Ag | Fluorescent antibody fusion protein, its production and use |
| JP5947802B2 (ja) | 2010-11-05 | 2016-07-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ミックスモードクロマトグラフィーによる抗体捕捉の最適化方法 |
| MX354663B (es) | 2011-06-22 | 2018-03-14 | Hoffmann La Roche | Eliminación de células diana por parte de células t citotóxicas específicas de virus utilizando complejos que comprenden mhc de clase i. |
| RU2502798C2 (ru) * | 2012-02-22 | 2013-12-27 | Общество с ограниченной ответственностью "Фармако Биотех" | КЛЕТОЧНАЯ ЛИНИЯ huFSHIK, СЕКРЕТИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ЧЕЛОВЕЧЕСКИЙ ФСГ |
| WO2014067642A1 (en) | 2012-11-05 | 2014-05-08 | Mab Discovery Gmbh | Method for the production of multispecific antibodies |
| EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
| WO2014096015A1 (en) | 2012-12-21 | 2014-06-26 | F. Hoffmann-La Roche Ag | Disulfide-linked multivalent mhc class i comprising multi-function proteins |
| US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| WO2021119234A1 (en) * | 2019-12-10 | 2021-06-17 | Horizon Pharma Ireland Ltd. | Glycosylated antibodies against insulin-like growth factor i receptor and uses thereof |
| IL302068A (en) | 2020-10-14 | 2023-06-01 | Viridian Therapeutics Inc | Preparations and methods for treating eye disease of the thyroid gland |
| US20230084477A1 (en) | 2021-08-10 | 2023-03-16 | Viridian Therapeutics, Inc. | Compositions, doses, and methods for treatment of thyroid eye disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US5202238A (en) * | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) * | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9022543D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| US5650508A (en) * | 1991-12-27 | 1997-07-22 | Georgia Tech Research Corporation | Peptide ketoamides |
| NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
| PT1914244E (pt) * | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
| US20030165502A1 (en) * | 2000-06-13 | 2003-09-04 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
| US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| US7553485B2 (en) * | 2002-01-18 | 2009-06-30 | Pierre Fabre Medicament | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof |
| NZ571508A (en) * | 2002-05-24 | 2010-05-28 | Schering Corp | Neutralizing human anti-IGFR antibody |
| EP1613658B1 (en) * | 2003-04-02 | 2012-03-14 | F. Hoffmann-La Roche AG | Antibodies against insulin-like growth factor i receptor and uses thereof |
| AR046071A1 (es) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| US20070142627A1 (en) * | 2003-08-01 | 2007-06-21 | Chugai Seiyaku Kabushiki Kaisha | Sugar-chain-altered anti-hm1.24 antibody |
| JP4794303B2 (ja) * | 2003-10-10 | 2011-10-19 | 中外製薬株式会社 | 固形腫瘍治療剤 |
-
2007
- 2007-04-05 US US11/784,029 patent/US20080014203A1/en not_active Abandoned
- 2007-04-10 AU AU2007236199A patent/AU2007236199B2/en active Active
- 2007-04-10 CA CA2647181A patent/CA2647181C/en active Active
- 2007-04-10 WO PCT/EP2007/003165 patent/WO2007115814A2/en not_active Ceased
- 2007-04-10 UA UAA200812606A patent/UA95284C2/ru unknown
- 2007-04-10 KR KR1020087024802A patent/KR101276513B1/ko active Active
- 2007-04-10 EP EP07724106A patent/EP2007810B1/en active Active
- 2007-04-10 KR KR1020127002545A patent/KR20120028396A/ko not_active Ceased
- 2007-04-10 CA CA3081707A patent/CA3081707A1/en active Pending
- 2007-04-10 MX MX2008012950A patent/MX2008012950A/es active IP Right Grant
- 2007-04-10 ES ES07724106T patent/ES2403075T3/es active Active
- 2007-04-10 NZ NZ571414A patent/NZ571414A/en not_active IP Right Cessation
- 2007-04-10 RU RU2008144290/10A patent/RU2541765C2/ru active
- 2007-04-10 BR BRPI0710185A patent/BRPI0710185B8/pt active IP Right Grant
- 2007-04-10 EP EP10180713A patent/EP2363417A1/en not_active Withdrawn
- 2007-04-10 JP JP2009504628A patent/JP4718634B2/ja active Active
- 2007-04-10 CN CN2007800128287A patent/CN101421305B/zh active Active
- 2007-04-11 AR ARP070101538A patent/AR060592A1/es active IP Right Grant
-
2008
- 2008-09-19 CR CR10301A patent/CR10301A/es not_active Application Discontinuation
- 2008-09-25 NO NO20084082A patent/NO20084082L/no not_active Application Discontinuation
- 2008-09-25 IL IL194397A patent/IL194397A/en active IP Right Grant
- 2008-10-08 ZA ZA200808597A patent/ZA200808597B/xx unknown
- 2008-10-09 EC EC2008008816A patent/ECSP088816A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP088816A (es) | Anticuerpos contra el receptor del factor de crecimiento i similar a la insulina y usos de los mismos | |
| ECSP088814A (es) | Anticuerpos fucosilados | |
| CR10810A (es) | Anticuerpos contra el receptor del factor de crecimiento similar a la insulina i y la utilizacion de los mismos | |
| UY32764A (es) | Preparaciones insulinicas que comprenden metionina | |
| MX2019007584A (es) | Combinaciones de compuesto de fgf21/agonista de glp-1r con una proporcion de actividades optimizada. | |
| GT200600046A (es) | Terapia de combinacion | |
| CL2012000620A1 (es) | Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20. | |
| AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| CR20120310A (es) | Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico | |
| PE20081899A1 (es) | Anticuerpos anti-ige | |
| AR033439A1 (es) | Composicion que comprende adyuvante prebiotico para disminuir procesos inflamatorios y activacion anormal de parametros no especificos inmunitarios | |
| CL2013001436A1 (es) | Composicion que comprende al menos una n-acetil-lactosamina, al menos un oligosacarido sialilado y al menos un oligosacarido fucosilado; y su uso para la prevencion y/o tratamiento de las condiciones de la piel y enfermedades de la piel. | |
| CL2013001471A1 (es) | Composicion que comprende al menos una n-acetil-lactosamina, al menos un oligosacarido sialilado y al menos un oligosacarido fucosilado y un hidrolizado que comprende proteinas parcialmente y/o completamente hidrolizadas; y su uso para la prevencion y/o tratamiento de las condiciones de la piel y enfermedades de la piel. | |
| CL2007002841A1 (es) | Compuestos derivados de indol, antagonistas del receptor de glucagion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes mellitus tipo 2, hiperglucemia, diabetes o resistencia a la insulina. | |
| CR7786A (es) | Anticuerpos neutralizantes contra gdf-8 y el uso de los mismos | |
| PE20130328A1 (es) | Composicion de cereal hidrolizado | |
| CL2007002147A1 (es) | Bebida que tiene un contenido de energia total de menor a 4,06 kcal por 100 g y comprende 0,04 a 0,4% de catequinas (c)y un endulzante no nutritivo, donde la dulzura (s) es menor a 7% y se cumple la condicion 40<(s/c)<115; y uso de dicha bebida para el manejo del peso corporal. | |
| AR096184A1 (es) | Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpos para cd22-fármaco | |
| PE20080187A1 (es) | Agonistas receptores de eritropoietina | |
| UA117480C2 (uk) | Лікування цукрового діабету за допомогою складу інсуліну тривалої дії | |
| PA8806501A1 (es) | Triazolotriazinas y triazolopirazinas y su uso | |
| AR046187A1 (es) | Uso de poli - alfa- 1,4- glucanos lineales como almidones resistentes | |
| ITRM20080529A1 (it) | Uso della l-chinurenina e suoi derivati per la prevenzione ed il trattamento del diabete mellito di tipo 1. | |
| MX2024002214A (es) | Farmaco de combinacion. | |
| WO2009108168A3 (en) | Gold nanoparticle glycoconjugates for generating igg specific for the carbohydrate |